| Identification | Back Directory | [Name]
Benzeneacetic acid, α-[(3,5-dimethoxyphenyl)methylene]-4-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenoxy]-, methyl ester | [CAS]
249886-47-3 | [Synonyms]
CLX0921
THR0921
THR-0921
CLX-0921
THR 0921
CLX 0921
Benzeneacetic acid, α-[(3,5-dimethoxyphenyl)methylene]-4-[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenoxy]-, methyl ester | [Molecular Formula]
C28H25NO7S | [MOL File]
249886-47-3.mol | [Molecular Weight]
519.57 |
| Hazard Information | Back Directory | [Description]
CLX 0921 is a peroxisome proliferator-activated receptor（PPAR）gamma agonist potentially for the treatment of type 2 diabetes. | [Uses]
CLX-0921 is an orally active PPARγ agonist with an IC50 of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes[1]. | [in vivo]
CLX-0921 (3.1-12.5 mg/kg; oral gavage; once daily; for 19 days) shows dose-dependent antihyperglycemic activity[1]. | Animal Model: | Male C57BL/KsJ-db/db and C57BL/6J-ob/ob mice (7-week-old)[1] | | Dosage: | 3.1 mg/kg, 6.3 mg/kg, and 12.5 mg/kg | | Administration: | Oral gavage; once daily; for 19 days | | Result: | Showed dose-dependent antihyperglycemic activity.
|
| [IC 50]
PPARγ: 1.54 μM (IC50) | [References]
[1] Debendranath Dey, et al. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metabolism. 2003 Aug;52(8):1012-8. DOI:10.1016/s0026-0495(03)00152-5 |
|
|